Mesoblast Limited's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Mesoblast Limited's ROI in the fourth quarter of 2025?
Mesoblast Limited recorded a cumulative net loss of $-102 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on investment (ROI) of -15.38%.

Within the Healthcare sector 309 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from 3196 to 3255.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Jun 30 2024) IV. Quarter
Y / Y Investment Change TTM	20.04 %	10.36 %	1.73 %	3.32 %	-5.9 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	714	682	579	682	559
Return On Investment (TTM)	-15.38 %	-14.06 %	-15.01 %	-14.84 %	-15.9 %
MESO's Overall Ranking	# 3255	# 3196	#	#	#
Seq. Investment Change TTM	6.17 %	6.76 %	-1.17 %	7.16 %	-2.39 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-102	-88	-88	-88	-88

MESO Company Profile >> Back to MESO Roi Comparisons >> See Annual MESO Return On Investment

Return On Investment MESO's Ranking
Within:	No.
Industry	# 33
Sector	# 310
Overall	# 3255

Return On Investment Statistics
High	Average	Low
-12.67 %	-14.8 %	-16.8 %
(Jun 30 2020)		(Jun 30 2024)

News about Mesoblast Limited Return on Investment ROI

for the Mesoblast Secures U.S. Origin Designation for Cell Therapies Amidst Industry Headwinds Strategic A...

September 26, 2025

Mesoblast Achieves Strategic Milestone: Cell Therapy Products Secure U.S. Origin Designation Amidst Industry Challenges Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a pioneering force in the development of allogeneic cellular medicines for inflammatory diseases, has made a significant announcement confirming that its allogeneic cell therapy products are manufactured from U.S. donors and designated as U.S. origin products. This designation, revealed on September 26, 2025, ensures that these products are exempt from tariffs typically applied to imported branded or patented pharmaceutical products. This new status bolsters Mesoblast s competitive positioning in the global pharmaceutical market, allowing the company to optimize its supply chain and potentially reduce costs associated with international trade regulations. U.S. Origin Designation: A Strategic Advantage In the complex landscape of pharmaceuticals, where supply chain disruptions and trade regulations can profoundly affect business operations, Mesoblast s U.S. origin designation emerges as a strategic advantage. By sourcing cells from U.S. donors and utilizing domestic manufacturing facilities, Mesoblast is effectively insulating its allogeneic cell therapy line from the financial and operational uncertainties posed by international tariffs. This designation not only fortifies the company s commitment to leveraging U.S.-based resources but also exemplifies its proactive approach to adapting to regulatory landscapes.

Financial Statements
Mesoblast Limited's IV. Quarter Investments	$ 714 Millions	MESO's Balance sheet
Mesoblast Limited's IV. Quarter Income	$ -102 Millions	Quarterly MESO's Income Statement
MESO's Income by Division		See MESO's Income by Division

MESO Annual Return On Investment	(Jun 30 2025) 2025	(Jun 30 2024) 2024	(Jun 30 2023) 2023	(Jun 30 2022) 2022	(Jun 30 2021) 2021
Total Investments in Millions	769	579	606	598	679
Y / Y Investment Growth	32.9 %	-4.57 %	1.44 %	-11.9 %	3.33 %
Net Income in Millions	-102	-88	-82	-91	-99
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-13.28 %	-15.2 %	-13.5 %	-15.28 %	-14.56 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
MESO's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for MESO's Competitors
Subscribers only: Roi for Mesoblast Limited's Suppliers
Subscribers only: Return On Investment for MESO's Customers

Other Ratios
MESO's Roa	MESO's Inventory Turnover Ratio	MESO's Growth Rates	MESO's Dividend Statistics
	MESO's Profitability Ratios	MESO's Asset Turnover Ratio	MESO's Dividend Growth
MESO's Roe	MESO's Valuation Ratios	MESO's Financial Strength Ratios	MESO's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2025, within Healthcare Sector

ROI

Date modified: 2026-07-07T12:24:10+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.